Play all audios:
In 2016, FDA Oncology approved five new molecular entities and 17 efficacy supplements, including six accelerated approvals, 17 priority reviews, and 11 approvals of breakthrough-designated
therapies. The FDA also approved five companion diagnostics, including a liquid biopsy test. One new anti-PD-L1 antibody was approved, along with six supplementary approvals of
anti-PD-1/PD-L1 antibodies. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your
institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal
Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices
may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support
REFERENCES * Rosenberg, J. E. _ et al_. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based
chemotherapy: a single-arm, multicenter, phase 2 trial. _Lancet_ 387, 1909–1920 (2016). Article CAS Google Scholar * Blumenthal, G. M. & Pazdur, R. Response rate as an approval
endpoint in oncology: back to the future. _JAMA Oncol._ 2, 780–781 (2016). Article Google Scholar * Reck, M. _ et al_. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell
lung cancer. _N. Engl. J. Med._ 375, 1823–1833 (2016). Article CAS Google Scholar * Ferris, R. L. _ et al_. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. _N. Engl.
J. Med._ 375, 1856–1867 (2016). Article Google Scholar * Roberts, A. W. _ et al_. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. _N. Engl. J. Med._ 374, 311–322
(2016). Article CAS Google Scholar * Kazandjian, D. _ et al_. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell
lung cancer. _Oncologist_ 21, 974–980 (2016). Article Google Scholar * Blumenthal, G. M., Mansfield, E. & Pazdur, R. Next-generation sequencing in oncology in the era of precision
medicine. _JAMA Oncol._ 2, 13–14 (2016). Article Google Scholar * Sherman, R. E. _ et al_. Real-world evidence — what is it and what can it tell us? _N. Engl. J. Med._ 375, 2293–2297
(2016). Article Google Scholar * National Cancer Institute. Cancer Moonshot Blue Ribbon Panel Report 2016. _Cancer.gov_
https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel (2016). * Pazdur, R. Leveraging the power of collaboration — FDA's new Oncology Center of
Excellence. _FDA Voice blog_ http://blogs.fda.gov/fdavoice/index.php/2016/06/leveraging-the-power-of-collaboration-fdas-new-oncology-center-of-excellence/ (2016). Google Scholar Download
references ACKNOWLEDGEMENTS The authors would like to thank Kirsten Goldberg from the Office of Hematology and Oncology Products, FDA for her assistance with editing this manuscript. AUTHOR
INFORMATION AUTHORS AND AFFILIATIONS * Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10,903 New Hampshire Avenue, Silver Spring, 20903, Maryland, USA Gideon M.
Blumenthal & Richard Pazdur Authors * Gideon M. Blumenthal View author publications You can also search for this author inPubMed Google Scholar * Richard Pazdur View author publications
You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Gideon M. Blumenthal. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no
competing financial interests. SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION S1 (TABLE) Summary of FDA oncology drug approvals in 2016 (PDF 76 kb) RELATED LINKS RELATED LINKS FURTHER
INFORMATION Hematology/Oncology (Cancer) Approvals & Safety Notifications RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Blumenthal, G., Pazdur, R.
Approvals in 2016: the march of the checkpoint inhibitors. _Nat Rev Clin Oncol_ 14, 131–132 (2017). https://doi.org/10.1038/nrclinonc.2017.15 Download citation * Published: 20 February 2017
* Issue Date: March 2017 * DOI: https://doi.org/10.1038/nrclinonc.2017.15 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link
Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative